TICKERNOMICS Sign up
Last Update: 2024-12-27 15:29:16
BioXcel Therapeutics Inc. ( BTAI ) https://www.bioxceltherapeutics.com
0.37USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-87.60%
BTAI
SPY
32.66%
-98.29%
BTAI
SPY
108.59%
-96.30%
BTAI
SPY
302.52%
BTAI
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
15.77
184.42
1.76
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.22
6.93
-0.18
-146.62
0.00
-2.57
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-7146.26
100.00
-3393.38
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
5.3136
-65.27
-65.68
0.27
Other Earnings and Cash Flow Stats:
BioXcel Therapeutics Inc. ( BTAI ) Net Income TTM ($MM) is -71.00
BioXcel Therapeutics Inc. ( BTAI ) Operating Income TTM ($MM) is -76.48
BioXcel Therapeutics Inc. ( BTAI ) Owners' Earnings Annual ($MM) is 0.00
BioXcel Therapeutics Inc. ( BTAI ) Current Price to Owners' Earnings ratio is 0.00
BioXcel Therapeutics Inc. ( BTAI ) EBITDA TTM ($MM) is -76.17
BioXcel Therapeutics Inc. ( BTAI ) EBITDA Margin is -3393.38%
Capital Allocation:
BioXcel Therapeutics Inc. ( BTAI ) has paid 0.00 dividends per share and bought back -13.122 million shares in the past 12 months
BioXcel Therapeutics Inc. ( BTAI ) has increased its debt by 109.08 million USD in the last 12 months
Capital Structure:
BioXcel Therapeutics Inc. ( BTAI ) Interest-bearing Debt ($MM) as of last quarter is 209
BioXcel Therapeutics Inc. ( BTAI ) Annual Working Capital Investments ($MM) are 6
BioXcel Therapeutics Inc. ( BTAI ) Book Value ($MM) as of last quarter is -86
BioXcel Therapeutics Inc. ( BTAI ) Debt/Capital as of last quarter is -245%
Other Balance Sheet Stats:
BioXcel Therapeutics Inc. ( BTAI ) has 40 million in cash on hand as of last quarter
BioXcel Therapeutics Inc. ( BTAI ) has 25 million of liabilities due within 12 months, and long term debt 104 as of last quarter
BioXcel Therapeutics Inc. ( BTAI ) has 42 common shares outstanding as of last quarter
BioXcel Therapeutics Inc. ( BTAI ) has 0 million USD of preferred stock value
Academic Scores:
BioXcel Therapeutics Inc. ( BTAI ) Altman Z-Score is -22.51 as of last quarter
BioXcel Therapeutics Inc. ( BTAI ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
BioXcel Therapeutics Inc. ( BTAI ) largest shareholder is owning shares at 0.00 ($MM) value
O'Neill Vincent(an insider) Sold 165 shares of BioXcel Therapeutics Inc. ( BTAI ) for the amount of $58.13 on 2024-12-16
20.06% of BioXcel Therapeutics Inc. ( BTAI ) is held by insiders, and 8.76% is held by institutions
BioXcel Therapeutics Inc. ( BTAI ) went public on 2018-03-08
Other BioXcel Therapeutics Inc. ( BTAI ) financial metrics:
FCF:-84.09
Unlevered Free Cash Flow:-136.57
EPS:-1.29
Operating Margin:-7146.26
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:63.76
Beta:0.27
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About BioXcel Therapeutics Inc. ( BTAI ) :
BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of rare forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.